白蛋白生理功能再认识

王菁菁; 刘丽改; 谢雯

doi:10.12449/JCH250302

白蛋白生理功能再认识

DOI: 10.12449/JCH250302

首都医科大学附属北京地坛医院肝病中心，北京 100015

基金项目:

北京市医院管理中心“杨帆”计划临床技术创新项目 (ZLRK202334)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：王菁菁、刘丽改负责查阅文献，撰写论文；谢雯负责拟定文章思路，修改并最终定稿。

详细信息

通信作者:
谢雯， xiewen6218@163.com （ORCID： 0000-0002-7314-8175）

计量
- 文章访问数: 1291
- HTML全文浏览量: 100
- PDF下载量: 80
- 被引次数: 0
出版历程
- 收稿日期: 2024-12-11
- 录用日期: 2024-12-18
- 出版日期: 2025-03-25

A re-understanding of the physiological function of albumin

Liver Research Center，Beijing Ditan Hospital，Capital Medical University，Beijing 100015，China

Research funding:

Beijing Hospital Management Center “Yangfan” Plan Clinical Technology Innovation Project (ZLRK202334)

More Information

Corresponding author: XIE Wen， xiewen6218@163.com （ORCID： 0000-0002-7314-8175）

摘要

摘要: 白蛋白作为肝脏合成的重要蛋白质，是反映肝功能的重要标志之一，可随着肝损伤的进展而发生结构和功能变化。在疾病状态下，白蛋白不仅是数量减少，功能也受损，在此基础上提出了“有效白蛋白”概念。本文对白蛋白的生理结构和功能、在疾病状态下的生理功能变化及有效白蛋白的研究进展进行阐述，以探索更精准的白蛋白临床应用策略。
- 白蛋白类 /
- 有效白蛋白 /
- 肝硬化
Abstract: As an important protein synthesized by the liver， albumin is one of the most important markers for liver function， and its structure and function change with the progression of liver injury. Latest studies have shown that albumin in the disease state is not only reduced in quantity， but also damaged in quality， and thus the concept of “effective albumin” was proposed. This article elaborates on the research advances in the physiological structure and function of albumin， the changes of physiological function in the disease state， and the research advances in effective albumin， so as to explore precise strategies for the clinical application of albumin.
- Albumins /
- Effective Albumin /
- Liver cirrhosis

HTML全文

参考文献(32)

[1]	WU NJ, LIU TT, TIAN MM, et al. Albumin, an interesting and functionally diverse protein, varies from‘native’ to‘effective’(Review)[J]. Mol Med Rep, 2024, 29( 2): 24. DOI: 10.3892/mmr.2023.13147.
[2]	TUFONI M, BALDASSARRE M, ZACCHERINI G, et al. Hemodynamic and systemic effects of albumin in patients with advanced liver disease[J]. Curr Hepatol Rep, 2020, 19( 3): 147- 158. DOI: 10.1007/s11901-020-00521-1.
[3]	COLOMBO G, CLERICI M, GIUSTARINI D, et al. Redox albuminomics: Oxidized albumin in human diseases[J]. Antioxid Redox Signal, 2012, 17( 11): 1515- 1527. DOI: 10.1089/ars.2012.4702.
[4]	ALCARAZ-QUILES J, CASULLERAS M, OETTL K, et al. Oxidized albumin triggers a cytokine storm in leukocytes through P38 mitogen-activated protein kinase: Role in systemic inflammation in decompensated cirrhosis[J]. Hepatology, 2018, 68( 5): 1937- 1952. DOI: 10.1002/hep.30135.
[5]	TAVERNA M, MARIE AL, MIRA JP, et al. Specific antioxidant properties of human serum albumin[J]. Ann Intensive Care, 2013, 3( 1): 4. DOI: 10.1186/2110-5820-3-4.
[6]	TORRES LN, CHUNG KK, SALGADO CL, et al. Low-volume resuscitation with normal saline is associated with microvascular endothelial dysfunction after hemorrhage in rats, compared to colloids and balanced crystalloids[J]. Crit Care, 2017, 21( 1): 160. DOI: 10.1186/s13054-017-1745-7.
[7]	CARACENI P, RIGGIO O, ANGELI P, et al. Long-term albumin administration in decompensated cirrhosis(ANSWER): An open-label randomised trial[J]. Lancet, 2018, 391( 10138): 2417- 2429. DOI: 10.1016/S0140-6736(18)30840-7.
[8]	POMPILI E, ZACCHERINI G, PIANO S, et al. Real-world experience with long-term albumin in patients with cirrhosis and ascites[J]. JHEP Rep, 2024, 6( 12): 101221. DOI: 10.1016/j.jhepr.2024.101221.
[9]	CHRIS RUNKEN M, CARACENI P, FERNANDEZ J, et al. The cost-effectiveness of albumin in the treatment of decompensated cirrhosis in Germany, Italy, and Spain[J]. Health Econ Rev, 2019, 9( 1): 22. DOI: 10.1186/s13561-019-0237-7.
[10]	CARACENI P, PAVESI M, BALDASSARRE M, et al. The use of human albumin in patients with cirrhosis: A European survey[J]. Expert Rev Gastroenterol Hepatol, 2018, 12( 6): 625- 632. DOI: 10.1080/17474124.2018.1460203.
[11]	CARACENI P, ANGELI P, PRATI D, et al. AISF-SIMTI position paper on the appropriate use of albumin in patients with liver cirrhosis: A 2020 update[J]. Blood Transfus, 2021, 19( 1): 9- 13. DOI: 10.2450/2020.0414-20.
[12]	BERNARDI M, ANGELI P, CLARIA J, et al. Albumin in decompensated cirrhosis: New concepts and perspectives[J]. Gut, 2020, 69( 6): 1127- 1138. DOI: 10.1136/gutjnl-2019-318843.
[13]	DOMENICALI M, BALDASSARRE M, GIANNONE FA, et al. Posttranscriptional changes of serum albumin: Clinical and prognostic significance in hospitalized patients with cirrhosis[J]. Hepatology, 2014, 60( 6): 1851- 1860. DOI: 10.1002/hep.27322.
[14]	BALDASSARRE M, NALDI M, ZACCHERINI G, et al. Determination of effective albumin in patients with decompensated cirrhosis: Clinical and prognostic implications[J]. Hepatology, 2021, 74( 4): 2058- 2073. DOI: 10.1002/hep.31798.
[15]	CASTRO-NARRO G, MOCTEZUMA-VELÁZQUEZ C, MALE-VELÁZQUEZ R, et al. Position statement on the use of albumin in liver cirrhosis[J]. Ann Hepatol, 2022, 27( 4): 100708. DOI: 10.1016/j.aohep.2022.100708.
[16]	POMPILI E, BALDASSARRE M, IANNONE G, et al. Long-term albumin improves the outcomes of patients with decompensated cirrhosis and diabetes mellitus: Post hoc analysis of the ANSWER trial[J]. Liver Int, 2024, 44( 9): 2108- 2113. DOI: 10.1111/liv.16020.
[17]	ZACCHERINI G, BALDASSARRE M, TUFONI M, et al. Correction and prevention of hyponatremia in patients with cirrhosis and ascites: Post hoc analysis of the ANSWER study database[J]. Am J Gastroenterol, 2023, 118( 1): 168- 173. DOI: 10.14309/ajg.0000000000001995.
[18]	FERNÁNDEZ J, ANGELI P, TREBICKA J, et al. Efficacy of albumin treatment for patients with cirrhosis and infections unrelated to spontaneous bacterial peritonitis[J]. Clin Gastroenterol Hepatol, 2020, 18( 4): 963- 973. e 14. DOI: 10.1016/j.cgh.2019.07.055.
[19]	NALDI M, BALDASSARRE M, DOMENICALI M, et al. Mass spectrometry characterization of circulating human serum albumin microheterogeneity in patients with alcoholic hepatitis[J]. J Pharm Biomed Anal, 2016, 122: 141- 147. DOI: 10.1016/j.jpba.2016.01.048.
[20]	DAS S, MARAS JS, HUSSAIN MS, et al. Hyperoxidized albumin modulates neutrophils to induce oxidative stress and inflammation in severe alcoholic hepatitis[J]. Hepatology, 2017, 65( 2): 631- 646. DOI: 10.1002/hep.28897.
[21]	JING WH, JIANG MY, FU XX, et al. Self-assembly drug-albumin nanocomposites for nonalcoholic fatty liver disease treatment[J]. Int J Biol Macromol, 2022, 214: 697- 707. DOI: 10.1016/j.ijbiomac.2022.06.167.
[22]	JALAN R, BERNARDI M. Effective albumin concentration and cirrhosis mortality: From concept to reality[J]. J Hepatol, 2013, 59( 5): 918- 920. DOI: 10.1016/j.jhep.2013.08.001.
[23]	KAZMIERCZAK SC, GURACHEVSKY A, MATTHES G, et al. Electron spin resonance spectroscopy of serum albumin: A novel new test for cancer diagnosis and monitoring[J]. Clin Chem, 2006, 52( 11): 2129- 2134. DOI: 10.1373/clinchem.2006.073148.
[24]	WATANABE H, IMAFUKU T, OTAGIRI M, et al. Clinical implications associated with the posttranslational modification-induced functional impairment of albumin in oxidative stress-related diseases[J]. J Pharm Sci, 2017, 106( 9): 2195- 2203. DOI: 10.1016/j.xphs.2017.03.002.
[25]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64( 4): 1249- 1264. DOI: 10.1002/hep.28740.
[26]	XIAO LL, ZHANG F, ZHAO YL, et al. Using advanced oxidation protein products and ischaemia-modified albumin to monitor oxidative stress levels in patients with drug-induced liver injury[J]. Sci Rep, 2020, 10( 1): 18128. DOI: 10.1038/s41598-020-75141-2.
[27]	LAKIS R, SAUVAGE FL, PINAULT E, et al. Semi-synthetic human albumin isoforms: Production, structure, binding capacities and influence on a routine laboratory test[J]. Int J Biol Macromol, 2023, 250: 126239. DOI: 10.1016/j.ijbiomac.2023.126239.
[28]	RAHALI MA, LAKIS R, SAUVAGE FL, et al. Posttranslational-modifications of human-serum-albumin analysis by a top-down approach validated by a comprehensive bottom-up analysis[J]. J Chromatogr B Analyt Technol Biomed Life Sci, 2023, 1224: 123740. DOI: 10.1016/j.jchromb.2023.123740.
[29]	CHEN CY, TSAI WL, LIN PJ, et al. The value of serum ischemia-modified albumin for assessing liver function in patients with chronic liver disease[J]. Clin Chem Lab Med, 2011, 49( 11): 1817- 1821. DOI: 10.1515/CCLM.2011.675.
[30]	GIANNONE FA, DOMENICALI M, BALDASSARRE M, et al. Ischaemia-modified albumin: A marker of bacterial infection in hospitalized patients with cirrhosis[J]. Liver Int, 2015, 35( 11): 2425- 2432. DOI: 10.1111/liv.12860.
[31]	SUN LJ, WANG Q, LIU MX, et al. Albumin binding function is a novel biomarker for early liver damage and disease progression in non-alcoholic fatty liver disease[J]. Endocrine, 2020, 69( 2): 294- 302. DOI: 10.1007/s12020-020-02319-z.
[32]	TADA S, YASUKAWA K, YATOMI Y, et al. A simple colorimetric assay to determine the concentration and proportion of human mercaptalbumin[J]. Pract Lab Med, 2022, 31: e00281. DOI: 10.1016/j.plabm.2022.e00281.